The MIC 50 and MIC 90 values of doripenem, determined by Etest, for 110 isolates of Burkholderia pseudomallei were 0.5 and 0.75 g/ml, respectively. There were significant correlations between MICs determined by Etest and MICs determined by agar dilution, MICs determined by Etest and inhibition zone size, and MICs determined by agar dilution and inhibition zone size.
within the reference limits. A distribution of the MICs for doripenem determined by Etest for 110 strains of B. pseudomallei is shown in Table 1 . Etest results showed doripenem MICs ranging from 0.19 to 2 g/ml, and the MIC 50 and the MIC 90 values were 0.5 and 0.75 g/ml, respectively. The MIC 50 and MIC 90 values of doripenem, determined by agar dilution for 30 strains of B. pseudomallei, were 1 and 1.5 g/ml, respectively. The inhibition zone diameters of doripenem determined for 30 strains of B. pseudomallei ranged from 24 to 36 mm. There was a significant correlation between the MICs determined by Etest and the MICs determined by agar dilution (r of 0.9; P of Ͻ0.001), the MICs determined by Etest and the inhibition zone diameters (r of Ϫ0.7; P of Ͻ0.001), and the MICs determined by agar dilution and the inhibition zone diameters (r of Ϫ0.7; P of Ͻ0.001), as shown in Fig. 1 .
The MIC breakpoint recommended by the CLSI for imipenem-susceptible B. pseudomallei, imipenem-susceptible P. aeruginosa, and meropenem-susceptible P. aeruginosa is Յ4 g/ml. The MIC breakpoint recommended by the FDA for imipenem-susceptible P. aeruginosa and meropenem-susceptible P. aeruginosa is also Յ4 g/ml. The MIC breakpoint recommended by the CLSI for meropenem-susceptible Burkholderia cepacia is Յ4 g/ml. However, the breakpoints for the MIC and inhibition zone diameter of doripenem for B. pseudomallei are not available. The U.S. FDA-approved breakpoints of doripenem for P. aeruginosa were a MIC of Յ2 g/ml and an inhibition zone diameter of Ն24 mm. If the aforementioned breakpoints were used to determine susceptibility of B. pseudomallei to doripenem, all isolates of B. pseudomallei are considered susceptible to doripenem, according to inhibition zone diameter and MICs determined by Etest; more than 90% of B. pseudomallei isolates are considered susceptible to doripenem, according to MICs determined by agar dilution. The susceptibility profiles of B. pseudomallei to imipenem and The inhibition zone diameters of doripenem for B. pseudomallei were significantly correlated with the MICs determined by Etest or agar dilution. Therefore, Kirby-Bauer disk diffusion could be used to determine in the vitro activity of doripenem against B. pseudomallei. However, the MICs of doripenem determined by agar dilution for B. pseudomallei observed in our study were twofold higher than those determined by Etest. Nevertheless, the MIC 90 of doripenem determined by agar dilution was Յ2 g/ml.
Ceftazidime is the conventional agent used as therapy for acute severe melioidosis (12) . Imipenem and meropenem were also found to be effective and safe when used as therapy for acute severe melioidosis (1, 9) , and they are considered to be alternative therapeutic agents (15) . Since the in vitro activity of doripenem against B. pseudomallei is comparable to the activity of imipenem and meropenem against B. pseudomallei, doripenem should be an effective therapy for melioidosis. However, a clinical trial is required to fully establish the efficacy and safety of doripenem used as therapy for melioidosis. 
